What the literature
just published.

[Evaluation of Serum LL-37 Levels in Patients with Brucellosis and Their Relationship with Clinical Course].

Mikrobiyoloji bulteni · 2026

This study aimed to determine the serum levels of the LL-37 molecule, associated with the pathophysiology of Brucellosis, in patients diagnosed with Brucellosis and to investigate the relationship between these levels and the clinical course of the disease. The study included 45 acute, 30 subacute, 26 chronic and 19 relapsed patients diagnosed according to clinical, bacteriological and serologic results as Brucellosis, as well as 60 healthy volunteers. Serum LL-37 levels were measured using the enzyme-linked immunosorbent assay method and the results were compared with the clinical data of the

A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.

The Journal of sports medicine and physical fitness · 2026

The pursuit of pharmacological enhancement in sport has evolved from the widespread use of anabolic-androgenic steroids (AAS) to novel agents such as peptides and peptide analogues. Marketed as more selective and ostensibly safer alternatives, peptides-including growth hormone secretagogues (e.g., Ipamorelin), growth hormone-releasing hormone analogues (e.g., CJC-1295, Sermorelin), and synthetic fragments (e.g., Frag 176-191, KPV)-are promoted for muscle growth, fat metabolism, recovery, and anti-inflammatory effects. Their pharmacological profiles, including enhanced stability and receptor se

A Phase II Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade (PD-1/CTLA-4) in Patients With Locally Advanced Non-Small Cell Lung Cancer

2026-01-01

This study will enroll patients with locally advanced non-small cell lung cancer (NSCLC). Patients will receive neoadjuvant chemotherapy combined with dual immune checkpoint blockade (PD-1/CTLA-4), bevacizumab and thymosin alpha 1, followed by concurrent chemoradiotherapy, and finally consolidation therapy with dual immune checkpoint blockade (PD-1/CTLA-4), surufatinib and thymosin alpha 1. The study aims to evaluate the efficacy and safety of this treatment regimen.

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI

2026-02-02

This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.

Achieving Sustained Weight Control Via Exercise, Nutrition & Drugs (Mazdutide) (ASCEND- 1 Trial)

2026-04

Obesity is a chronic, progressive, and relapsing disease. Although lifestyle interventions and anti-obesity medications are effective for inducing weight loss, evidence regarding their role in long-term weight maintenance after pharmacologically induced weight reduction remains limited. In addition, the high cost and potential adverse effects of weight-loss medications restrict their prolonged use, and it is unclear whether low dose medication, intensive life style intervention or together can serve as an effective strategy for weight maintenance. This randomized controlled trial aims to eval

Angiogenesis and inflammation in the retinopathy risk of insulin and semaglutide - a review.

International journal of retina and vitreous · 2026

To critically evaluate evidence supporting the angiogenesis-inflammation hypothesis in diabetic retinopathy (DR); to examine the roles of angiogenic growth factors and inflammatory cytokines in the biphasic effects of insulin on DR - early worsening followed by long-term risk reduction; and to explore broader implications of this hypothesis, including potential biphasic effects of semaglutide due to its insulinotropic action and strategies to mitigate the transient DR exacerbation associated with insulin and insulin secretagogues.

Assessment of the Effectiveness of Comprehensive Cardiac Rehabilitation and Identification of Factors Modulating Its Results

2026-01-03

Cardiovascular diseases, especially after life-saving surgeries, require comprehensive cardiac rehabilitation (CR). We know that the effectiveness of CR varies among patients. The main goal of this study is to understand which factors-psychological, physical, cognitive, biochemical, and hormonal-influence the success and long-term durability of the recovery process. These findings will help us create more effective and personalized treatment programs. Who is Being Studied and What is Being Assessed? Study Group: 150 patients of both sexes, aged 50-80 years, hospitalized in the cardiac rehabil

Beyond weight loss: tirzepatide as a dual GIP/GLP-1 receptor agonist for obstructive sleep apnea.

Current opinion in endocrinology, diabetes, and obesity · 2026

This review summarizes emerging evidence on the use of the dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide in improving obstructive sleep apnea (OSA) outcomes in individuals with obesity.

Bioequivalence of Survodutide (BI 456906) When Administered Via Pre-filled Syringe (Formulation A) and Pre Filled Pen (Formulation B2) in Male and Female Trial Participants Who Are Healthy or Otherwise Healthy With Overweight/Obesity (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Trial)

2026-03-03

The goal of this study is to find out whether different formulations of survodutide given by different delivery methods is taken up in the body in a similar way. Participants visit the study site regularly. During study visits, the doctors collect information about participants' health. To assess the study endpoints, participants regularly have blood samples taken.

Breaking a mitochondrial danger-STING feed-forward amplifier preserves alveolar-capillary architecture and dampens interferon-chemokine signaling in acute lung injury.

Tissue & cell · 2026

Acute lung injury (ALI) is defined by disruption of alveolar-capillary architecture, inflammatory remodeling of the parenchyma, and barrier dysfunction. Mitochondrial structural damage can promote release of mitochondrial danger signals that engage cytosolic DNA sensing and amplify tissue injury. Here, we tested whether dual targeting of mitochondrial structure-function (elamipretide, ELM) and STING signaling (H151) preserves lung tissue organization. At 24 h post intratracheal lipopolysaccharide, lung architecture was assessed histologically, and BALF and lung tissue were analyzed for barrier

Early targets and progressive deterioration in cardiac performance in response to chronically modified cardiac troponin I.

American journal of physiology. Heart and circulatory physiology · 2026

Protein kinase C (PKC) targeted thin filament cardiac troponin I (cTnI) Ser43/45 phosphorylation (p-S43/45) increases during heart failure (HF). Chronic cTnI p-S43/45 causes contractile dysfunction in cardiac myocytes, but the in vivo impact is less clear. To investigate the in vivo impact of this cluster, three lines of transgenic mice were generated with high (HE-), moderate (ME-), and low (LE-) phosphomimetic cTnIS43/45D (SD) replacement of endogenous cTnI within sarcomere thin filament. Each mouse line developed chronic in vivo and/or cellular contractile dysfunction, which initiated struc

Effect of a Progressive Resistance Exercise Program on Muscle Mass and Physical Function During a Tirzepatide Induced Weight Loss in Overweight and Obese Females: a Randomised Parallel Group Study

2026-04-01

This study aims to investigate the effect that a structured, progressive resistance exercise program may have on maintaining the muscle mass and physical function of overweight/ obese females whilst they experience a tirzepatide (GLP-1/GIP receptor agonist) induced weight loss. Overweight and obese females aged 25-50 will be recruited for the study, they will require a BMI of \>30 or \>27 with one obesity related comorbidity (excluding diabetes). They will be screened, prescribed tirzepatide and then randomly assigned to either the intervention (GLP-1/GIP + Exercise) or the control group (GLP

Efficacy and safety of Tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis.

Disease-a-month : DM · 2026

Obesity-related heart failure with preserved ejection fraction (HFpEF) is associated with high morbidity and limited therapeutic options. Tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has demonstrated reductions in cardiovascular mortality and worsening heart failure events in a recent randomized controlled trial. However, pooled evidence for tirzepatide's cardiovascular and clinical effects in HFpEF remains limited. Moreover, head-to-head comparisons of tirzepatide with semaglutide, another incretin-mimetic the

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)

2026-02-02

This Phase 3 study evaluates the efficacy and safety of once-weekly subcutaneous tirzepatide (a dual GIP and GLP-1 receptor agonist) at 5 mg, 10 mg, or 15 mg versus placebo, each used with a reduced-calorie diet and increased physical activity, in adults without type 2 diabetes who have obesity or are overweight with weight-related comorbidities. The primary efficacy assessment is at Week 72. Participants with prediabetes at randomization may continue in an additional long-term treatment period to assess progression to type 2 diabetes and longer-term weight outcomes.

Elamipretide Hydrochloride.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026

Elamipretide: First Approval.

Drugs · 2026

Elamipretide (Forzinity™) is a mitochondrial cardiolipin binder being developed by Stealth BioTherapeutics for the treatment of a range of disorders featuring mitochondrial dysfunction. In September 2025, elamipretide was granted accelerated approval in the USA for use to improve muscle strength in adult and pediatric patients with Barth syndrome weighing ≥ 30 kg. With this accelerated approval, elamipretide became the first disease-specific treatment approved for Barth syndrome, an ultra-rare X-linked recessive genetic disorder. Elamipretide is also under phase III clinical development for us

FDA-Approved Drugs Containing D-Amino Acids: A Historical and Developmental Perspective.

Drug development research · 2026

d-Amino acids, the non-natural enantiomers of l-amino acids, have emerged as powerful tools in peptide drug development due to their unique biochemical properties. Their resistance to proteolytic degradation, enhanced conformational rigidity, and reduced immunogenicity make them especially valuable in designing long-acting and receptor-selective therapeutics. Since the mid-20th century, more than 20 FDA-approved drugs have incorporated at least one d-amino acid into their structure, spanning indications from infectious diseases and endocrine disorders to rare dermatologic conditions and diagno

Fibrillar and Micellar Aggregation of Semaglutide and Formation of a Chiral-Imprinted Glass.

Biomacromolecules · 2026

Semaglutide is a therapeutically important lipopeptide that comprises a lipidated peptide with a glucagon-like peptide-1 (GLP-1) sequence, and may be prone to aggregation. We show that semaglutide in low pH 2.4 solutions forms β-sheet fibrils, in contrast to the oligomeric and micellar structures formed at higher pH. Based on cryo-TEM images showing twisted fibrils and the modeling of SAXS data (and with knowledge from fiber XRD) and molecular dynamics simulations, a model for the β-sheet structure is proposed, which comprises curved β-strands arranged in an antiparallel fashion around a core

High-Fat Diet Promotes Glycolysis in Hepatocellular Carcinoma by Suppressing Hepatic Kisspeptin Signaling in Mice.

Molecular carcinogenesis · 2026

Hepatocellular carcinoma is a leading cause of cancer-related mortality worldwide, with metabolic syndrome emerging as a major risk factor. However, the molecular mechanisms underlying the association between metabolic syndrome and hepatocellular carcinoma progression are not fully understood. Here, we investigated the role of kisspeptin signaling in hepatocellular carcinoma progression under metabolic dysregulation. High-fat diet feeding significantly decreased hepatic kisspeptin receptor expression in mice. Integrated transcriptomic and metabolomic analyses revealed that kisspeptin primarily

Hyperoside stabilizes ACAT1 to promote fatty acid oxidation and attenuate kidney fibrosis via the L-carnitine-SIRT3 axis.

Phytomedicine : international journal of phytotherapy and phytopharmacology · 2026

Kidney fibrosis represents a key pathological process driving the progression of chronic kidney disease (CKD) and is closely associated with mitochondrial impairment and altered lipid metabolism. Hyperoside, a major flavonoid glycoside from Abelmoschus manihot, has shown anti-fibrotic activity, yet its mechanistic role in renal fibrosis remains unclear.

Integrated transcriptomics and miRNA-mRNA network analysis reveals Kisspeptin-10 mediated regulation of EMT and apoptosis in glioblastoma.

Computational biology and chemistry · 2026

Glioblastoma multiforme (GB) is the most aggressive and lethal primary brain tumor, with limited biomarkers for diagnosis and therapeutic targeting. This study aimed to investigate the regulatory effects of Kisspeptin-10 on epithelial-mesenchymal transition (EMT) and apoptosis in GB by integrating transcriptomic profiling, network analysis, and in-vitro validation. Kisspeptin-10, a metastasis-suppressor peptide known to modulate EMT and apoptotic pathways in several cancers, has not been previously explored in GB. Differentially expressed genes (DEGs) were identified from publicly available GE

Kisspeptin Restores Placental mTOR Signaling and Improves Glucose Homeostasis Mediators Disrupted by Maternal Hypothyroidism in Rats.

Acta physiologica (Oxford, England) · 2026

Reduced placental mTOR signaling is associated with intrauterine growth restriction and impaired maternal and placental metabolism. Since maternal hypothyroidism induces intrauterine growth restriction, and maternal treatment with kisspeptin-10 (Kp10) has been shown to improve feto-placental development in hypothyroid rats, this study aimed to evaluate the effects of maternal hypothyroidism, with and without kisspeptin-10 treatment, on maternal energy homeostasis and placental expression of mTOR and glucose metabolism mediators.

Kisspeptin-10 attenuates pulmonary arterial hypertension via restoration of mitochondrial function in pulmonary artery smooth muscle cells.

Neuropeptides · 2026

Mitochondrial dysfunction and dysregulated mitophagy in pulmonary artery smooth muscle cells (PASMCs) critically drive pulmonary arterial hypertension (PAH). Here we show that Kisspeptin-10, acting via its receptor GPR54, markedly attenuates PAH in the SU5416/hypoxia mouse model. The administration of kisspeptin-10 resulted in a considerable reduction in the systolic pressure of the right ventricle, as well as in the level of right ventricular hypertrophy and pulmonary vascular remodeling. Mechanistically, Kisspeptin-10 restored mitochondrial membrane potential, ATP production, and cytochrome

Kisspeptin-10 Promotes Hormone Secretion, Ovarian Follicles Development and Fecundity via PI3K/AKT/ERK Signal Pathway in Mice.

Molecular reproduction and development · 2026

The present study aimed to comprehensively elucidate how KP-10 modulates hormone secretion, the proliferation and autophagy of ovarian follicles by regulating in-vivo and in-vitro levels of associated genes and proteins.

Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells.

Cytotechnology · 2026

Hepatocellular steatosis, an early stage within the non-alcoholic fatty liver disease (NAFLD) spectrum, is characterized by excessive lipid accumulation and oxidative stress in hepatocytes. This study examined the protective role of Lysine-Proline-Valine (KPV), an endogenous tripeptide derived from α-melanocyte-stimulating hormone, against oleic acid (OA)-induced oxidative damage and lipid accumulation in hepatic epithelial HepG2 cells. OA treatment markedly enhanced hepatic lipid deposition by upregulation of fatty acid synthase (FAS) expression. Treatment with KPV (100 µg/mL) significantly a

Mechanisms of Anti-Oxidants, N-Acetylcysteine and Elamipretide (SS-31), on Ozone-Induced Airway Hyperresponsiveness and Mucus Hypersecretion.

Lung · 2026

Ozone (O₃) exposure induces acute airway injury characterized by airway hyperresponsiveness (AHR) and airway mucus hypersecretion (AMH). Oxidative stress and mitochondria-derived reactive oxygen species (mtROS) are key contributors. We investigated and compared the protective mechanisms of N-acetylcysteine (NAC) and the mitochondria-targeted antioxidant Elamipretide (SS-31) in O₃-induced airway inflammation, AHR and AMH.

Microenvironment-responsive injectable dynamic hydrogel for sequential antioxidant and tissue regeneration therapy of radiation-induced skin injury.

Bioactive materials · 2026

Radiotherapy is essential for cancer treatment, yet radiation-induced skin injury (RISI) remains a major clinical challenge due to reactive oxygen species (ROS) accumulation, metabolic dysregulation, and the limited efficacy of single-modality therapies in modulating the oxidative-inflammatory microenvironment. To overcome this limitation, we have developed a multifunctional injectable hydrogel, HCG@CDs, by cross-linking biocompatible carboxymethyl chitosan (CMCS) with oxidized hyaluronic acid (OHA) conjugated to the Glycyl-L-Histidyl-L-Lysine-Copper(II) complex (GHK-Cu

Mitochondria dysfunction and increased expression of WNT5A and BNIP3 in tenocytes obtained from patients with tendinopathy.

JSES international · 2026

Tendinopathy is a significant source of pain and functional impairment, with contributions from various extrinsic and intrinsic factors. Prior studies have demonstrated the role of mitochondria (MT) dysfunction in a murine model of supraspinatus tendinopathy, with improvement in tendon structure following treatment with the mitochondrial protectant agent Szeto-Schiller-31 (elamipretide). However, there is very little information available on mitochondrial function in human tendinopathy. The purpose of this study is to compare MT function in human tenocytes obtained from pathologic tendons of p

Mitochondria-derived peptide MOTS-c alleviates hyperoxia-induced bronchopulmonary dysplasia in neonatal mice by activating Nrf2 pathway.

European journal of pharmacology · 2026

Oxidative stress play key roles in the pathogenesis of bronchopulmonary dysplasia (BPD). MOTS-c is a mitochondria-derived peptide containing 16 amino acids that is reported to be involved in the treatment of oxidative stress-related diseases. However, whether MOTS-c functions on hyperoxia-induced BPD remains unknown. The purpose of this study was to investigate the potential therapeutic effect and mechanism of MOTS-c on hyperoxia-induced BPD. Here, hyperoxia (70% O

Molecular interaction modes of the host-defense peptide cathelicidin LL-37 and its mutants dictate diverse antimicrobial activities.

Nanoscale · 2026

The host-defense peptide cathelicidin LL37 is an innate immune defense peptide with broad-spectrum antimicrobial effects. Experiments showed that the antimicrobial activity of LL37(17-29), the active core of LL37, was associated with peptide aggregation and fibrillization. Although wild-type (WT) LL37(17-29) aggregated into densely packed fibrils with strong antimicrobial activity, the F17S mutation exhibited a weaker antimicrobial effect, and I24K totally abolished the antimicrobial activity, with no fibrils formed. To uncover the mechanisms of the distinct antimicrobial activities, we explor

Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair.

Diabetology & metabolic syndrome · 2026

Next-generation therapies for hepatocellular carcinoma: CAR-T cell and anticancer peptide synergy.

International journal of biological macromolecules · 2026

Hepatocellular carcinoma (HCC), the most common primary liver cancer, is characterized by late diagnosis, limited treatment efficacy, and a highly immunosuppressive tumour microenvironment. Chronic liver injury, fibrosis, and inflammation are central to HCC pathogenesis, leading to genetic and epigenetic changes, particularly under oxidative stress from reactive oxygen species (ROS). Aberrant activation of pathways such as Wnt/β-catenin, contributes to uncontrolled proliferation, resistance to apoptosis, and metastasis. This review emphasizes how immunotherapy particularly immune checkpoint in

Oral Health Considerations and Dental Management Guidelines for Semaglutide Medications.

Canadian journal of diabetes · 2026

Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated clinically meaningful weight loss effects in patients with Type 2 diabetes and high BMI, and dental practitioners and physicians are often encountering patients who take these medications. Semaglutide is known to be associated with several systemic side effects, including delayed gastric emptying, belching, reflux and nausea, nutritional changes, and gastrointestinal discomfort. Systemic effects secondarily manifest in the oral cavity, and as a result, patients taking semaglutide may present with xerostomia (dry mouth),

Osteoprotective effects of the neuropeptide VIP: insights from triple cultures of human osteocytes, osteoblasts, and osteoclasts.

Translational research : the journal of laboratory and clinical medicine · 2026

Bone remodelling is a dynamic process of osteoblastic bone formation and osteoclastic bone resorption, regulated by local, paracrine and endocrine factors, in which osteocytes act as orchestrators of bone homeostasis. Among these regulatory factors, the neuropeptide VIP (vasoactive intestinal peptide) has demonstrated osteoprotective effects by inhibiting osteoclastogenesis and promoting osteoblast differentiation. However, its potential role in osteocyte biology remains unexplored. In this study, we investigated the effect of VIP on the differentiation of primary human osteocytes. We describe

Pine pollen fiber alleviates constipation induced by loperamide in mice: focus on gastrointestinal motility-related hormones, short-chain fatty acids, and gut microbiota changes.

Food & function · 2026

Constipation, a prevalent gastrointestinal disorder, urgently requires safe and effective intervention strategies. Natural dietary fibers have gained attention for their potential to alleviate constipation through multiple mechanisms. This study investigated the therapeutic effects of pine pollen fiber (PPF), a by-product from pine pollen processing, on loperamide-induced constipation in mice. The mice were administered low or high doses of PPF for 14 consecutive days, and we evaluated constipation-related indicators, serum levels of gastrointestinal peptides and neurotransmitters, gut microbi

PKCδ-Drp1 Axis Mediates VIP-Induced Mitochondrial Fragmentation and Metabolic Crisis in Nasopharyngeal Carcinoma.

Drug development research · 2026

In nasopharyngeal carcinoma, mitochondria often function abnormally. However, the precise signals that cause excessive mitochondrial division are still undefined. Levels of the neuropeptide Vasoactive Intestinal Peptide are altered in NPC tissues. How VIP influences the metabolic behavior of cancer cells is not well established. Our experiments utilized established NPC cell lines. We tested how physiological concentrations (10-100 nM) of VIP exposure affect survival and mitochondrial integrity. Morphology was analyzed using fluorescence staining. We measured functional outputs, including react

Real-world Effectiveness and Dosing Patterns of Tirzepatide: A Multicentre Retrospective Observational Study in the Netherlands

2026-04-01

Tirzepatide is one of the new medications for the treatment of obesity. In clinical research people treated with Tirzepatide have weight loss up to 21%. But there is only a little bit of research showing the effect of Tirzepatide in clinical practice. In this retrospective observational study the investigators will evaluate the effectiveness of tirzepatide in routine clinical practice among adults with obesity in the Netherlands.The main questions it aims to answer are: * How much weight do patients lose after six months of treatment with tirzepatide combined with lifestyle coaching? * How i

Relationship between kisspeptin-10, neurokinin B and dynorphin A in the course of normal and delayed puberty in ewes.

Journal of veterinary research · 2026

Kisspeptin (KiSS), neurokinin B (NKB) and dynorphin A (Dyn A) participate in the neuroendocrine regulation of reproductive system development and functioning; however, their roles in the onset of sexual maturity and pathomechanism of delayed puberty have not yet been fully elucidated. The aim of the study was to determine changes in the kisspeptin-10 (KiSS-10), NKB and Dyn A concentration in blood plasma collected from ewe lambs during puberty in relation to the first ovulation time, and to examine the relationship between these neuropeptides.

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Sports medicine (Auckland, N.Z.) · 2026

Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel "gray market" of unapproved compounds has emerged, operating largely outside of regulatory oversight. Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent

Safety and efficacy of tirzepatide in transplant recipients: a systematic review and meta-analysis.

Frontiers in pharmacology · 2026

Tirzepatide has demonstrated cardiovascular and metabolic benefits in the general population; however, evidence in post-transplant patients is very limited. The aim of this systematic review and meta-analysis is to evaluate the safety and efficacy of tirzepatide in solid organ transplant recipients.

Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Narrative Synthesis.

AACE endocrinology and diabetes · 2026

Recent observational studies report conflicting evidence on whether semaglutide use is associated with non-arteritic anterior ischemic optic neuropathy (NAION). This systematic review synthesizes available evidence and critically evaluates bias and confounding.

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

2026-02

The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.

Semaglutide in obesity and type 2 diabetes: A review of clinical trial evidence from 1 to 5 semaglutide treatment effect in people with obesity program.

Indian journal of pharmacology · 2026

Obesity and type 2 diabetes mellitus (T2DM) are widespread health concerns that often coexist, contributing to increased cardiometabolic risks and premature death. Despite advancements in both lifestyle interventions and medical treatments, achieving lasting weight reduction and stable glycemic control remains a major clinical challenge. This review examines findings from the semaglutide treatment effect in people with obesity 1 (STEP) 1-5 trials, which assessed the effectiveness, safety, and long-term outcomes of once-weekly semaglutide 2.4 mg for weight management in adults. These trials inc

Synergistic mitochondrial homeostasis regulation and cholinergic circuits reconstruction via a one-step synthesized multifunctional hydrogel facilitates spinal cord injury repair.

Bioactive materials · 2026

Neural Stem Cells (NSCs) possess significant potential to form new neural networks. However, following spinal cord injury (SCI), mitochondrial dysfunction leads to the excessive accumulation of reactive oxygen species (ROS), which severely impairs the neuronal differentiation of endogenous NSCs and thus hinders neural regeneration. Here, we report a multifunctional hydrogel, Poly(LA-Cho)/SS31 (PLCS), synthesized in one step using lipoic acid (LA), choline bicarbonate, and elamipretide (SS31). PLCS hydrogel exhibits injectability, self-healing ability, tissue adhesion, and sequential drug relea

Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study.

Diabetes research and clinical practice · 2026

Evidence suggests sodium glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists may reduce the onset/progression of dementia. The effect of the dual GLP1/GIP receptor agonist tirzepatide on dementia outcomes remains unknown. We compared tirzepatide, semaglutide and SGLT2-i in relation to incident dementia in patients with type 2 diabetes.

The Laccase-like Property of GHK-Cu and Its Applications in Colorimetric Sensing of Phenolic Compounds.

Biosensors · 2026

Laccase plays an important role in the detection and degradation of phenolic compounds, but it is limited by its cost and stability. In this study, the laccase-like property of copper peptide (GHK-Cu) has been revealed. In terms of enzymatic reaction kinetics, GHK-Cu has a

Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026

To comprehensively synthesize and quantify the multi-organ effects of tirzepatide across 10 health domains beyond its primary indications for type 2 diabetes and obesity.

Tirzepatide in Metabolic Diseases: Clinical Efficacy and Safety Beyond Diabetes and Obesity.

Medicinal research reviews · 2026

Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has attracted substantial attention for its exceptional efficacy in managing type 2 diabetes and obesity. Emerging evidence suggests that tirzepatide may also exert broad therapeutic benefits in cardiovascular diseases, metabolic dysfunction-associated steatotic liver disease, and chronic kidney disease. However, its potential clinical risks are increasingly being recognized. This review begins by outlining the structural and pharmacological advantages of tirzepati

Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis.

Diabetes, obesity & metabolism · 2026

To evaluate the effects of tirzepatide on physical function in adults with overweight or obesity.